| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimalarials | 326 | 2025 | 1469 | 32.030 |
Why?
|
| Plasmodium falciparum | 307 | 2025 | 1511 | 28.660 |
Why?
|
| Malaria, Falciparum | 182 | 2025 | 1183 | 21.870 |
Why?
|
| Artemisinins | 97 | 2025 | 548 | 15.980 |
Why?
|
| Drug Resistance | 106 | 2025 | 1472 | 14.200 |
Why?
|
| Malaria | 136 | 2025 | 1730 | 11.520 |
Why?
|
| Cysteine Endopeptidases | 94 | 2024 | 962 | 7.580 |
Why?
|
| Protozoan Proteins | 75 | 2025 | 1228 | 7.260 |
Why?
|
| Uganda | 154 | 2025 | 3173 | 5.470 |
Why?
|
| Pyrimethamine | 43 | 2025 | 234 | 4.270 |
Why?
|
| Cysteine Proteinase Inhibitors | 53 | 2024 | 471 | 4.220 |
Why?
|
| Amodiaquine | 37 | 2025 | 122 | 4.110 |
Why?
|
| Quinolines | 47 | 2025 | 1007 | 4.060 |
Why?
|
| Multidrug Resistance-Associated Proteins | 23 | 2025 | 238 | 4.020 |
Why?
|
| Sulfadoxine | 40 | 2025 | 214 | 3.900 |
Why?
|
| Polymorphism, Genetic | 35 | 2024 | 3668 | 3.870 |
Why?
|
| Parasitemia | 27 | 2025 | 298 | 3.070 |
Why?
|
| Parasitic Sensitivity Tests | 46 | 2025 | 221 | 3.060 |
Why?
|
| Ethanolamines | 28 | 2017 | 280 | 3.040 |
Why?
|
| Plasmodium | 25 | 2023 | 235 | 3.040 |
Why?
|
| Chloroquine | 42 | 2025 | 295 | 3.000 |
Why?
|
| Fluorenes | 28 | 2017 | 283 | 2.990 |
Why?
|
| Folic Acid Antagonists | 12 | 2024 | 92 | 2.950 |
Why?
|
| Plasmodium berghei | 28 | 2025 | 122 | 2.870 |
Why?
|
| Aminoquinolines | 22 | 2021 | 181 | 2.850 |
Why?
|
| Alagille Syndrome | 8 | 2024 | 79 | 2.650 |
Why?
|
| Parasites | 8 | 2023 | 212 | 2.620 |
Why?
|
| Cholestasis | 13 | 2024 | 483 | 2.580 |
Why?
|
| Erythrocytes | 48 | 2025 | 1924 | 2.240 |
Why?
|
| Drug Combinations | 61 | 2025 | 2069 | 2.200 |
Why?
|
| Tropical Medicine | 4 | 2021 | 57 | 2.130 |
Why?
|
| Biliary Atresia | 11 | 2025 | 188 | 2.010 |
Why?
|
| Malaria, Vivax | 5 | 2022 | 142 | 1.860 |
Why?
|
| Inhibitory Concentration 50 | 35 | 2025 | 709 | 1.630 |
Why?
|
| Cysteine Proteases | 6 | 2022 | 83 | 1.590 |
Why?
|
| Infant | 134 | 2025 | 31637 | 1.550 |
Why?
|
| Membrane Transport Proteins | 22 | 2025 | 1593 | 1.520 |
Why?
|
| Africa | 19 | 2024 | 731 | 1.510 |
Why?
|
| Hemoglobins | 30 | 2014 | 1788 | 1.500 |
Why?
|
| Antigens, Protozoan | 14 | 2021 | 419 | 1.480 |
Why?
|
| Insecticide-Treated Bednets | 13 | 2022 | 165 | 1.470 |
Why?
|
| Child, Preschool | 140 | 2025 | 37943 | 1.440 |
Why?
|
| Malaria Vaccines | 4 | 2022 | 130 | 1.410 |
Why?
|
| Sesquiterpenes | 14 | 2020 | 274 | 1.390 |
Why?
|
| Boron Compounds | 8 | 2019 | 214 | 1.250 |
Why?
|
| Mosquito Control | 15 | 2022 | 385 | 1.250 |
Why?
|
| Structure-Activity Relationship | 72 | 2025 | 4781 | 1.240 |
Why?
|
| Drug Resistance, Multiple | 4 | 2024 | 239 | 1.240 |
Why?
|
| Chalcone | 10 | 2017 | 45 | 1.240 |
Why?
|
| Pregnancy Complications, Parasitic | 8 | 2025 | 201 | 1.200 |
Why?
|
| Proteasome Inhibitors | 7 | 2023 | 367 | 1.200 |
Why?
|
| Annonaceae | 5 | 2011 | 7 | 1.190 |
Why?
|
| Genes, Protozoan | 10 | 2024 | 133 | 1.170 |
Why?
|
| Child | 144 | 2025 | 71856 | 1.160 |
Why?
|
| DNA, Protozoan | 23 | 2018 | 362 | 1.150 |
Why?
|
| Plant Extracts | 5 | 2012 | 821 | 1.150 |
Why?
|
| Humans | 427 | 2025 | 770101 | 1.130 |
Why?
|
| Quinine | 8 | 2025 | 75 | 1.120 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 11 | 2022 | 176 | 0.970 |
Why?
|
| Mass Drug Administration | 5 | 2025 | 322 | 0.970 |
Why?
|
| Communicable Disease Control | 5 | 2020 | 658 | 0.960 |
Why?
|
| Peroxides | 7 | 2025 | 143 | 0.940 |
Why?
|
| Drug Therapy, Combination | 44 | 2025 | 5612 | 0.940 |
Why?
|
| Plasmodium malariae | 1 | 2024 | 7 | 0.900 |
Why?
|
| Lactones | 5 | 2018 | 277 | 0.870 |
Why?
|
| Sulfones | 8 | 2013 | 479 | 0.840 |
Why?
|
| Mutation | 35 | 2025 | 27015 | 0.830 |
Why?
|
| Global Health | 7 | 2024 | 2724 | 0.830 |
Why?
|
| Nucleic Acid Amplification Techniques | 5 | 2020 | 508 | 0.830 |
Why?
|
| Periodicals as Topic | 3 | 2021 | 1375 | 0.820 |
Why?
|
| Animals | 215 | 2025 | 239727 | 0.820 |
Why?
|
| Lopinavir | 7 | 2016 | 303 | 0.790 |
Why?
|
| Genotype | 33 | 2025 | 12581 | 0.790 |
Why?
|
| Azithromycin | 6 | 2025 | 784 | 0.780 |
Why?
|
| Insecticides | 8 | 2022 | 658 | 0.780 |
Why?
|
| Disease Eradication | 4 | 2019 | 263 | 0.780 |
Why?
|
| Asymptomatic Infections | 1 | 2024 | 192 | 0.780 |
Why?
|
| Antiprotozoal Agents | 10 | 2019 | 229 | 0.770 |
Why?
|
| Protease Inhibitors | 17 | 2013 | 911 | 0.770 |
Why?
|
| Aspartic Acid Endopeptidases | 8 | 2019 | 288 | 0.760 |
Why?
|
| Isatin | 9 | 2020 | 16 | 0.740 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2020 | 625 | 0.730 |
Why?
|
| HIV Protease Inhibitors | 8 | 2016 | 774 | 0.700 |
Why?
|
| Drug Design | 23 | 2021 | 1866 | 0.700 |
Why?
|
| Hemeproteins | 8 | 2025 | 85 | 0.670 |
Why?
|
| Antibodies, Protozoan | 7 | 2021 | 498 | 0.670 |
Why?
|
| Dipeptides | 9 | 2017 | 565 | 0.670 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2020 | 69 | 0.660 |
Why?
|
| Eukaryota | 3 | 2018 | 326 | 0.660 |
Why?
|
| Cleavage And Polyadenylation Specificity Factor | 2 | 2017 | 24 | 0.660 |
Why?
|
| Antiparasitic Agents | 6 | 2016 | 142 | 0.660 |
Why?
|
| Burkina Faso | 11 | 2024 | 169 | 0.650 |
Why?
|
| Leucine-tRNA Ligase | 2 | 2016 | 8 | 0.640 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3218 | 0.630 |
Why?
|
| Food Parasitology | 1 | 2019 | 17 | 0.630 |
Why?
|
| Plasmodium vivax | 6 | 2015 | 121 | 0.630 |
Why?
|
| Hepatitis C, Chronic | 5 | 2025 | 1210 | 0.630 |
Why?
|
| Hydrolysis | 16 | 2014 | 1201 | 0.630 |
Why?
|
| Genetic Fitness | 1 | 2021 | 178 | 0.620 |
Why?
|
| Primaquine | 6 | 2019 | 81 | 0.610 |
Why?
|
| Culicidae | 4 | 2024 | 283 | 0.610 |
Why?
|
| Helminthiasis | 1 | 2019 | 75 | 0.610 |
Why?
|
| Proteasome Endopeptidase Complex | 7 | 2023 | 1285 | 0.610 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 609 | 0.610 |
Why?
|
| Leucine | 7 | 2009 | 514 | 0.600 |
Why?
|
| Plants, Medicinal | 3 | 2019 | 242 | 0.600 |
Why?
|
| Drug Resistance, Microbial | 4 | 2019 | 646 | 0.600 |
Why?
|
| Hygiene | 2 | 2020 | 230 | 0.590 |
Why?
|
| Rotavirus Infections | 1 | 2019 | 107 | 0.590 |
Why?
|
| Dihydropteroate Synthase | 8 | 2011 | 44 | 0.590 |
Why?
|
| Rotavirus | 1 | 2019 | 120 | 0.590 |
Why?
|
| Seasons | 7 | 2023 | 1842 | 0.580 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 696 | 0.580 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 4 | 2018 | 81 | 0.570 |
Why?
|
| Pandemics | 5 | 2022 | 8440 | 0.570 |
Why?
|
| Clusiaceae | 5 | 2009 | 6 | 0.570 |
Why?
|
| Liver Transplantation | 7 | 2023 | 5275 | 0.560 |
Why?
|
| Female | 169 | 2025 | 415307 | 0.560 |
Why?
|
| Africa South of the Sahara | 7 | 2022 | 570 | 0.560 |
Why?
|
| Sickle Cell Trait | 4 | 2018 | 76 | 0.540 |
Why?
|
| Oils, Volatile | 2 | 2010 | 34 | 0.540 |
Why?
|
| Amino Acid Sequence | 31 | 2017 | 16916 | 0.540 |
Why?
|
| Sofosbuvir | 3 | 2025 | 186 | 0.530 |
Why?
|
| Anopheles | 4 | 2025 | 420 | 0.530 |
Why?
|
| Gene Deletion | 3 | 2021 | 2921 | 0.520 |
Why?
|
| Prevalence | 34 | 2024 | 17495 | 0.520 |
Why?
|
| Budgets | 1 | 2017 | 100 | 0.520 |
Why?
|
| Coinfection | 1 | 2024 | 1031 | 0.520 |
Why?
|
| Federal Government | 1 | 2017 | 153 | 0.510 |
Why?
|
| Disease Resistance | 2 | 2017 | 191 | 0.500 |
Why?
|
| Helminth Proteins | 3 | 2002 | 205 | 0.500 |
Why?
|
| Molecular Sequence Data | 30 | 2015 | 21816 | 0.500 |
Why?
|
| Pneumonia, Viral | 4 | 2022 | 3085 | 0.500 |
Why?
|
| Adamantane | 2 | 2025 | 155 | 0.490 |
Why?
|
| Biomedical Research | 3 | 2020 | 3691 | 0.480 |
Why?
|
| Genotyping Techniques | 3 | 2025 | 574 | 0.480 |
Why?
|
| Chemoprevention | 8 | 2023 | 542 | 0.480 |
Why?
|
| Politics | 1 | 2020 | 524 | 0.480 |
Why?
|
| Betacoronavirus | 3 | 2020 | 2678 | 0.480 |
Why?
|
| Chalcones | 4 | 2010 | 48 | 0.480 |
Why?
|
| Phthalimides | 3 | 2021 | 22 | 0.470 |
Why?
|
| Viral Vaccines | 1 | 2019 | 640 | 0.470 |
Why?
|
| Male | 141 | 2025 | 396789 | 0.460 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2022 | 388 | 0.460 |
Why?
|
| Molecular Structure | 25 | 2020 | 3835 | 0.460 |
Why?
|
| Financing, Government | 1 | 2017 | 343 | 0.450 |
Why?
|
| Trypanosomiasis, African | 4 | 2024 | 82 | 0.440 |
Why?
|
| Trypanosoma cruzi | 5 | 2012 | 388 | 0.430 |
Why?
|
| Cameroon | 8 | 2013 | 215 | 0.430 |
Why?
|
| Travel | 6 | 2021 | 671 | 0.420 |
Why?
|
| Health Care Costs | 2 | 2023 | 2484 | 0.420 |
Why?
|
| Antiviral Agents | 8 | 2025 | 4084 | 0.420 |
Why?
|
| Carbamates | 4 | 2024 | 347 | 0.420 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 655 | 0.410 |
Why?
|
| Research Support as Topic | 1 | 2017 | 610 | 0.410 |
Why?
|
| Drug Approval | 1 | 2019 | 604 | 0.410 |
Why?
|
| Life Cycle Stages | 9 | 2025 | 183 | 0.400 |
Why?
|
| Pruritus | 5 | 2024 | 510 | 0.400 |
Why?
|
| Acridones | 2 | 2025 | 4 | 0.400 |
Why?
|
| Piperazines | 6 | 2025 | 1782 | 0.400 |
Why?
|
| Sapindaceae | 1 | 2012 | 4 | 0.400 |
Why?
|
| Genetic Markers | 6 | 2014 | 2261 | 0.390 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 993 | 0.390 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2024 | 2729 | 0.380 |
Why?
|
| Ligases | 3 | 2023 | 208 | 0.380 |
Why?
|
| Adolescent | 54 | 2025 | 90652 | 0.380 |
Why?
|
| Fatty Liver | 3 | 2022 | 1725 | 0.380 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2012 | 549 | 0.380 |
Why?
|
| Refugees | 3 | 2024 | 322 | 0.380 |
Why?
|
| Sequence Homology, Amino Acid | 13 | 2017 | 3767 | 0.370 |
Why?
|
| Thiosemicarbazones | 6 | 2010 | 65 | 0.370 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2023 | 169 | 0.370 |
Why?
|
| Heme | 6 | 2021 | 363 | 0.370 |
Why?
|
| Insect Vectors | 2 | 2015 | 423 | 0.370 |
Why?
|
| Trypanocidal Agents | 5 | 2024 | 169 | 0.370 |
Why?
|
| Protein Folding | 9 | 2006 | 1645 | 0.370 |
Why?
|
| Anti-Bacterial Agents | 6 | 2025 | 9068 | 0.370 |
Why?
|
| Quinolones | 4 | 2020 | 340 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2025 | 13908 | 0.360 |
Why?
|
| Ferrous Compounds | 7 | 2017 | 143 | 0.360 |
Why?
|
| Emigration and Immigration | 1 | 2017 | 686 | 0.360 |
Why?
|
| Alkynes | 9 | 2020 | 558 | 0.360 |
Why?
|
| Ribavirin | 4 | 2025 | 426 | 0.360 |
Why?
|
| Tetracyclines | 2 | 2013 | 75 | 0.350 |
Why?
|
| Hemoglobin, Sickle | 1 | 2011 | 86 | 0.340 |
Why?
|
| International Cooperation | 4 | 2020 | 1271 | 0.340 |
Why?
|
| Xanthones | 2 | 2008 | 46 | 0.340 |
Why?
|
| Polymerase Chain Reaction | 18 | 2015 | 7564 | 0.330 |
Why?
|
| Drug Evaluation, Preclinical | 13 | 2019 | 1691 | 0.330 |
Why?
|
| Democratic Republic of the Congo | 3 | 2024 | 141 | 0.330 |
Why?
|
| Vacuoles | 8 | 2014 | 387 | 0.330 |
Why?
|
| Ritonavir | 5 | 2014 | 513 | 0.320 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 8 | 2020 | 234 | 0.320 |
Why?
|
| Evidence-Based Practice | 1 | 2017 | 863 | 0.320 |
Why?
|
| Leupeptins | 6 | 2013 | 129 | 0.320 |
Why?
|
| Pyrethrins | 2 | 2022 | 236 | 0.320 |
Why?
|
| Growth Disorders | 3 | 2024 | 436 | 0.320 |
Why?
|
| Pregnancy | 25 | 2025 | 30988 | 0.320 |
Why?
|
| Mosquito Vectors | 5 | 2025 | 374 | 0.320 |
Why?
|
| Health Policy | 4 | 2017 | 2234 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 25 | 2021 | 12135 | 0.310 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2010 | 325 | 0.310 |
Why?
|
| Cinnamates | 4 | 2013 | 65 | 0.310 |
Why?
|
| Hypertension, Portal | 2 | 2023 | 406 | 0.310 |
Why?
|
| Haplotypes | 8 | 2021 | 2971 | 0.310 |
Why?
|
| Family Characteristics | 3 | 2025 | 930 | 0.310 |
Why?
|
| Mefloquine | 4 | 2025 | 29 | 0.310 |
Why?
|
| Fever | 6 | 2019 | 1151 | 0.310 |
Why?
|
| Substrate Specificity | 12 | 2013 | 3210 | 0.300 |
Why?
|
| Pepstatins | 3 | 2008 | 13 | 0.300 |
Why?
|
| Genome, Protozoan | 3 | 2024 | 127 | 0.300 |
Why?
|
| Papain | 2 | 2006 | 71 | 0.300 |
Why?
|
| Molecular Docking Simulation | 11 | 2022 | 1024 | 0.300 |
Why?
|
| Recombinant Proteins | 15 | 2016 | 7720 | 0.290 |
Why?
|
| Models, Molecular | 23 | 2021 | 10506 | 0.290 |
Why?
|
| Magnoliopsida | 1 | 2009 | 89 | 0.290 |
Why?
|
| Treatment Outcome | 48 | 2025 | 66074 | 0.290 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2022 | 725 | 0.280 |
Why?
|
| Treatment Failure | 13 | 2014 | 2059 | 0.280 |
Why?
|
| Trypanosoma brucei rhodesiense | 2 | 2024 | 17 | 0.280 |
Why?
|
| Cohort Studies | 34 | 2025 | 34009 | 0.280 |
Why?
|
| Incidence | 24 | 2025 | 17629 | 0.270 |
Why?
|
| Peptides | 8 | 2022 | 5814 | 0.270 |
Why?
|
| Portoenterostomy, Hepatic | 4 | 2025 | 53 | 0.270 |
Why?
|
| Microsatellite Repeats | 4 | 2021 | 1139 | 0.270 |
Why?
|
| Longitudinal Studies | 21 | 2024 | 17825 | 0.270 |
Why?
|
| Nitriles | 3 | 2024 | 1129 | 0.270 |
Why?
|
| beta-Lactams | 3 | 2013 | 190 | 0.270 |
Why?
|
| Sequence Alignment | 10 | 2017 | 3248 | 0.260 |
Why?
|
| Case-Control Studies | 12 | 2023 | 20521 | 0.260 |
Why?
|
| Triterpenes | 1 | 2008 | 103 | 0.260 |
Why?
|
| Mice | 45 | 2025 | 97912 | 0.260 |
Why?
|
| Public Health | 4 | 2024 | 2512 | 0.260 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2024 | 73 | 0.260 |
Why?
|
| Recurrence | 10 | 2019 | 6823 | 0.260 |
Why?
|
| Placenta | 4 | 2025 | 2213 | 0.260 |
Why?
|
| Genome | 1 | 2016 | 2389 | 0.250 |
Why?
|
| Population Surveillance | 3 | 2016 | 2496 | 0.250 |
Why?
|
| Technology, Pharmaceutical | 2 | 2004 | 96 | 0.250 |
Why?
|
| Trypanosoma brucei brucei | 6 | 2017 | 268 | 0.250 |
Why?
|
| Protein Structure, Tertiary | 10 | 2014 | 5587 | 0.250 |
Why?
|
| Alleles | 8 | 2017 | 6654 | 0.250 |
Why?
|
| Disease Outbreaks | 3 | 2024 | 1974 | 0.250 |
Why?
|
| Plant Bark | 4 | 2010 | 19 | 0.240 |
Why?
|
| Immunoglobulin G | 4 | 2024 | 3960 | 0.240 |
Why?
|
| World Health Organization | 3 | 2024 | 876 | 0.240 |
Why?
|
| Phytotherapy | 1 | 2009 | 416 | 0.240 |
Why?
|
| Databases as Topic | 1 | 2007 | 507 | 0.240 |
Why?
|
| Hydrazines | 2 | 2019 | 193 | 0.240 |
Why?
|
| Bilirubin | 5 | 2023 | 617 | 0.230 |
Why?
|
| Image Cytometry | 1 | 2025 | 62 | 0.230 |
Why?
|
| History, 21st Century | 3 | 2021 | 1391 | 0.230 |
Why?
|
| Gene Frequency | 6 | 2025 | 3060 | 0.230 |
Why?
|
| Ethylenediamines | 2 | 2022 | 60 | 0.230 |
Why?
|
| Clinical Trials as Topic | 8 | 2024 | 7453 | 0.230 |
Why?
|
| Trophozoites | 2 | 2017 | 48 | 0.230 |
Why?
|
| Sequence Analysis, DNA | 9 | 2021 | 5570 | 0.230 |
Why?
|
| Societies, Medical | 1 | 2016 | 3521 | 0.230 |
Why?
|
| Microsomes, Liver | 5 | 2025 | 586 | 0.230 |
Why?
|
| South Sudan | 1 | 2024 | 13 | 0.220 |
Why?
|
| HIV Infections | 23 | 2023 | 30836 | 0.220 |
Why?
|
| Organelles | 1 | 2008 | 442 | 0.220 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2014 | 704 | 0.220 |
Why?
|
| Spiro Compounds | 2 | 2017 | 181 | 0.220 |
Why?
|
| Adult | 60 | 2025 | 226183 | 0.220 |
Why?
|
| Indoles | 4 | 2020 | 1872 | 0.220 |
Why?
|
| Benzothiepins | 1 | 2024 | 3 | 0.220 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 2 | 2017 | 246 | 0.220 |
Why?
|
| Asparagine | 2 | 2022 | 226 | 0.220 |
Why?
|
| Endopeptidases | 3 | 2002 | 714 | 0.220 |
Why?
|
| Tetraoxanes | 2 | 2014 | 3 | 0.220 |
Why?
|
| Protozoan Infections | 2 | 2008 | 166 | 0.210 |
Why?
|
| Benzoxazines | 5 | 2018 | 458 | 0.210 |
Why?
|
| History, 20th Century | 3 | 2021 | 2051 | 0.210 |
Why?
|
| Cell Survival | 12 | 2020 | 6447 | 0.210 |
Why?
|
| Hepatitis B e Antigens | 2 | 2022 | 178 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 2 | 2012 | 2470 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 14507 | 0.210 |
Why?
|
| Liver | 12 | 2025 | 12201 | 0.210 |
Why?
|
| Receptors, KIR | 1 | 2025 | 217 | 0.210 |
Why?
|
| Anticonvulsants | 2 | 2009 | 1558 | 0.210 |
Why?
|
| Antitubercular Agents | 4 | 2014 | 1377 | 0.210 |
Why?
|
| Drug Discovery | 4 | 2014 | 1396 | 0.210 |
Why?
|
| Receptor, EphA2 | 1 | 2024 | 62 | 0.200 |
Why?
|
| United States | 13 | 2023 | 71494 | 0.200 |
Why?
|
| Cyclopropanes | 6 | 2025 | 581 | 0.200 |
Why?
|
| Asia, Southeastern | 2 | 2025 | 155 | 0.200 |
Why?
|
| Doxycycline | 1 | 2006 | 484 | 0.200 |
Why?
|
| Genetic Variation | 7 | 2020 | 6419 | 0.200 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 6 | 2005 | 2216 | 0.200 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2024 | 108 | 0.200 |
Why?
|
| Plasmodium yoelii | 3 | 2025 | 43 | 0.200 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2003 | 96 | 0.200 |
Why?
|
| High-Throughput Screening Assays | 4 | 2014 | 1075 | 0.200 |
Why?
|
| Amides | 4 | 2019 | 720 | 0.200 |
Why?
|
| Single-Blind Method | 5 | 2019 | 1672 | 0.200 |
Why?
|
| Directed Molecular Evolution | 1 | 2024 | 185 | 0.200 |
Why?
|
| Catalytic Domain | 4 | 2017 | 1491 | 0.200 |
Why?
|
| Insurance, Health | 2 | 2023 | 1808 | 0.200 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2023 | 96 | 0.200 |
Why?
|
| Hepacivirus | 4 | 2024 | 1858 | 0.190 |
Why?
|
| Imines | 2 | 2013 | 87 | 0.190 |
Why?
|
| Vero Cells | 5 | 2021 | 589 | 0.190 |
Why?
|
| Globins | 3 | 2005 | 194 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 1911 | 0.190 |
Why?
|
| Infant, Newborn | 15 | 2025 | 23696 | 0.190 |
Why?
|
| Drug Administration Schedule | 7 | 2019 | 4366 | 0.190 |
Why?
|
| Time Factors | 17 | 2020 | 41829 | 0.190 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 196 | 0.190 |
Why?
|
| Enzyme Inhibitors | 6 | 2021 | 4752 | 0.190 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 213 | 0.190 |
Why?
|
| Molecular Conformation | 9 | 2021 | 1324 | 0.190 |
Why?
|
| Proguanil | 1 | 2022 | 8 | 0.190 |
Why?
|
| Asia | 3 | 2021 | 601 | 0.190 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2024 | 406 | 0.190 |
Why?
|
| Microscopy | 7 | 2022 | 1036 | 0.190 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 576 | 0.190 |
Why?
|
| Selection, Genetic | 2 | 2025 | 1105 | 0.190 |
Why?
|
| Immunization Schedule | 1 | 2022 | 193 | 0.190 |
Why?
|
| Niger | 5 | 2025 | 275 | 0.180 |
Why?
|
| Polymerization | 2 | 2021 | 243 | 0.180 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 288 | 0.180 |
Why?
|
| Drug Interactions | 8 | 2024 | 2146 | 0.180 |
Why?
|
| Sulfonamides | 3 | 2011 | 1867 | 0.180 |
Why?
|
| RNA, Messenger | 2 | 2017 | 15039 | 0.180 |
Why?
|
| Protein Structure, Secondary | 3 | 2017 | 2504 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2025 | 3450 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 2 | 2011 | 1472 | 0.180 |
Why?
|
| Biomarkers | 10 | 2025 | 23657 | 0.180 |
Why?
|
| Prospective Studies | 18 | 2024 | 44292 | 0.180 |
Why?
|
| Mosquito Nets | 2 | 2019 | 15 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 1646 | 0.180 |
Why?
|
| Lethal Dose 50 | 2 | 2011 | 152 | 0.180 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2008 | 781 | 0.170 |
Why?
|
| Latin America | 2 | 2020 | 402 | 0.170 |
Why?
|
| Medicaid | 2 | 2023 | 2133 | 0.170 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 2925 | 0.170 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 910 | 0.170 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 74 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 222 | 0.170 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 4455 | 0.170 |
Why?
|
| Protein Engineering | 1 | 2007 | 949 | 0.170 |
Why?
|
| Endemic Diseases | 4 | 2023 | 242 | 0.170 |
Why?
|
| Liver Diseases | 3 | 2022 | 1844 | 0.170 |
Why?
|
| Splenomegaly | 1 | 2021 | 158 | 0.170 |
Why?
|
| Stereoisomerism | 9 | 2017 | 1304 | 0.170 |
Why?
|
| Enzymes | 2 | 2013 | 467 | 0.170 |
Why?
|
| Toxoplasma | 2 | 2017 | 623 | 0.170 |
Why?
|
| Containment of Biohazards | 1 | 2020 | 29 | 0.160 |
Why?
|
| Varicose Veins | 1 | 2022 | 145 | 0.160 |
Why?
|
| HLA-C Antigens | 1 | 2021 | 164 | 0.160 |
Why?
|
| Community Health Workers | 1 | 2024 | 370 | 0.160 |
Why?
|
| Microspheres | 2 | 2014 | 774 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2004 | 971 | 0.160 |
Why?
|
| Peptide Library | 3 | 2009 | 629 | 0.160 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 209 | 0.160 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 337 | 0.160 |
Why?
|
| Immunoglobulin M | 1 | 2024 | 1288 | 0.160 |
Why?
|
| Fetal Growth Retardation | 1 | 2025 | 619 | 0.160 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2011 | 348 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2005 | 675 | 0.160 |
Why?
|
| Microwaves | 2 | 2019 | 228 | 0.160 |
Why?
|
| Antibody Affinity | 2 | 2021 | 324 | 0.160 |
Why?
|
| Blood | 3 | 2013 | 609 | 0.160 |
Why?
|
| Gambia | 1 | 2019 | 66 | 0.160 |
Why?
|
| Isoindoles | 1 | 2019 | 80 | 0.160 |
Why?
|
| Drainage | 1 | 2025 | 1054 | 0.150 |
Why?
|
| Seizures | 2 | 2009 | 3212 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 4200 | 0.150 |
Why?
|
| Indole Alkaloids | 2 | 2011 | 47 | 0.150 |
Why?
|
| Research Design | 5 | 2022 | 5530 | 0.150 |
Why?
|
| Virulence | 2 | 2014 | 1609 | 0.150 |
Why?
|
| Triazoles | 5 | 2016 | 963 | 0.150 |
Why?
|
| Amino Acids | 3 | 2023 | 2222 | 0.150 |
Why?
|
| Aziridines | 2 | 2011 | 43 | 0.150 |
Why?
|
| Nitroimidazoles | 1 | 2020 | 119 | 0.150 |
Why?
|
| Kinetics | 10 | 2014 | 10035 | 0.150 |
Why?
|
| Quinidine | 1 | 2019 | 83 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2023 | 371 | 0.150 |
Why?
|
| Anthelmintics | 1 | 2019 | 132 | 0.150 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2022 | 332 | 0.150 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2021 | 308 | 0.150 |
Why?
|
| Phenylcarbamates | 1 | 2019 | 91 | 0.150 |
Why?
|
| Azides | 3 | 2020 | 218 | 0.150 |
Why?
|
| Isoniazid | 1 | 2021 | 416 | 0.150 |
Why?
|
| Sumoylation | 1 | 2020 | 136 | 0.140 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2018 | 70 | 0.140 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 30886 | 0.140 |
Why?
|
| Hydrogen-Ion Concentration | 8 | 2015 | 4202 | 0.140 |
Why?
|
| Plasminogen Activators | 1 | 1998 | 141 | 0.140 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2019 | 112 | 0.140 |
Why?
|
| Invertebrates | 1 | 2019 | 180 | 0.140 |
Why?
|
| Cathepsin L | 4 | 2017 | 184 | 0.140 |
Why?
|
| Cryptosporidiosis | 1 | 2019 | 142 | 0.140 |
Why?
|
| Pneumocystis carinii | 2 | 2009 | 94 | 0.140 |
Why?
|
| Codon | 1 | 2019 | 516 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2022 | 488 | 0.140 |
Why?
|
| Young Adult | 23 | 2025 | 66894 | 0.140 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2019 | 158 | 0.140 |
Why?
|
| Prodrugs | 2 | 2012 | 456 | 0.140 |
Why?
|
| Gene Expression | 5 | 2017 | 9364 | 0.140 |
Why?
|
| Interleukin-10 | 1 | 2023 | 1275 | 0.140 |
Why?
|
| Benchmarking | 1 | 2023 | 926 | 0.140 |
Why?
|
| Quality of Life | 5 | 2023 | 15150 | 0.140 |
Why?
|
| Coronavirus | 1 | 2020 | 220 | 0.130 |
Why?
|
| Small Molecule Libraries | 5 | 2018 | 855 | 0.130 |
Why?
|
| Electron Transport Complex III | 3 | 2013 | 53 | 0.130 |
Why?
|
| Binding Sites | 9 | 2019 | 8734 | 0.130 |
Why?
|
| alpha-Globins | 1 | 2017 | 40 | 0.130 |
Why?
|
| RNA, Viral | 4 | 2016 | 5083 | 0.130 |
Why?
|
| Isoxazoles | 1 | 2019 | 290 | 0.130 |
Why?
|
| alpha-Thalassemia | 1 | 2018 | 98 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2002 | 796 | 0.130 |
Why?
|
| Diazepam | 2 | 2009 | 297 | 0.130 |
Why?
|
| Peptidomimetics | 2 | 2014 | 69 | 0.130 |
Why?
|
| Nasopharynx | 1 | 2019 | 318 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 345 | 0.130 |
Why?
|
| Green Fluorescent Proteins | 4 | 2011 | 3484 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 391 | 0.130 |
Why?
|
| Adenosine Triphosphatases | 2 | 2021 | 1188 | 0.130 |
Why?
|
| CD36 Antigens | 1 | 2017 | 215 | 0.130 |
Why?
|
| Chromatography, Liquid | 3 | 2020 | 2020 | 0.130 |
Why?
|
| DNA, Viral | 4 | 2022 | 3008 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 4 | 2021 | 644 | 0.130 |
Why?
|
| Genes, MDR | 2 | 2006 | 46 | 0.120 |
Why?
|
| Pyrroles | 2 | 2021 | 1027 | 0.120 |
Why?
|
| Alanine Transaminase | 4 | 2024 | 870 | 0.120 |
Why?
|
| Cryptosporidium parvum | 1 | 2016 | 95 | 0.120 |
Why?
|
| Midazolam | 2 | 2009 | 303 | 0.120 |
Why?
|
| Ion Channels | 1 | 2003 | 1534 | 0.120 |
Why?
|
| Molecular Epidemiology | 3 | 2021 | 491 | 0.120 |
Why?
|
| Kinins | 2 | 2013 | 15 | 0.120 |
Why?
|
| Veins | 1 | 2020 | 726 | 0.120 |
Why?
|
| Kininogens | 2 | 2013 | 35 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 780 | 0.120 |
Why?
|
| Liver Failure | 1 | 2019 | 444 | 0.120 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1407 | 0.120 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2019 | 1017 | 0.120 |
Why?
|
| Base Sequence | 8 | 2004 | 14603 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 8226 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 17889 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 681 | 0.120 |
Why?
|
| Leukocytes | 1 | 2023 | 1783 | 0.120 |
Why?
|
| Phenylalanine | 1 | 2017 | 428 | 0.120 |
Why?
|
| Capillaries | 1 | 2020 | 1080 | 0.120 |
Why?
|
| Sensitivity and Specificity | 7 | 2025 | 16313 | 0.120 |
Why?
|
| Geography | 6 | 2020 | 947 | 0.120 |
Why?
|
| Ubiquitination | 1 | 2020 | 871 | 0.120 |
Why?
|
| Anti-HIV Agents | 6 | 2018 | 6645 | 0.120 |
Why?
|
| Coordination Complexes | 1 | 2016 | 112 | 0.120 |
Why?
|
| Protein Binding | 9 | 2017 | 12718 | 0.110 |
Why?
|
| Interferon-alpha | 2 | 2016 | 790 | 0.110 |
Why?
|
| Amino Acid Substitution | 4 | 2014 | 1844 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2019 | 15915 | 0.110 |
Why?
|
| Enzyme Stability | 2 | 2009 | 390 | 0.110 |
Why?
|
| Plasmodium chabaudi | 2 | 2012 | 18 | 0.110 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 1257 | 0.110 |
Why?
|
| Africa, Western | 1 | 2015 | 103 | 0.110 |
Why?
|
| Risk Factors | 21 | 2024 | 62786 | 0.110 |
Why?
|
| Disease Progression | 4 | 2024 | 16153 | 0.110 |
Why?
|
| Amino Alcohols | 1 | 2014 | 21 | 0.110 |
Why?
|
| Telomere | 1 | 2023 | 1389 | 0.110 |
Why?
|
| Liver Cirrhosis | 3 | 2023 | 3548 | 0.110 |
Why?
|
| Quinones | 1 | 2015 | 162 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 8242 | 0.110 |
Why?
|
| Immunity | 1 | 2020 | 1012 | 0.110 |
Why?
|
| Ligands | 8 | 2021 | 5002 | 0.110 |
Why?
|
| Hydrogen Bonding | 5 | 2017 | 910 | 0.110 |
Why?
|
| Mutation, Missense | 3 | 2024 | 2150 | 0.110 |
Why?
|
| Biological Assay | 1 | 2018 | 798 | 0.110 |
Why?
|
| India | 1 | 2019 | 1586 | 0.110 |
Why?
|
| Toxoplasmosis | 1 | 2017 | 245 | 0.110 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 3665 | 0.110 |
Why?
|
| Saquinavir | 2 | 2011 | 61 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 4499 | 0.110 |
Why?
|
| Tetrazoles | 2 | 2013 | 291 | 0.110 |
Why?
|
| Amino Acid Motifs | 2 | 2010 | 1387 | 0.110 |
Why?
|
| Retrospective Studies | 10 | 2023 | 82371 | 0.110 |
Why?
|
| In Vitro Techniques | 4 | 2021 | 6781 | 0.100 |
Why?
|
| Drug Delivery Systems | 3 | 2012 | 2284 | 0.100 |
Why?
|
| Crystallography, X-Ray | 6 | 2016 | 3933 | 0.100 |
Why?
|
| Growth | 1 | 2014 | 269 | 0.100 |
Why?
|
| Salacia | 1 | 2013 | 1 | 0.100 |
Why?
|
| Nevirapine | 2 | 2014 | 268 | 0.100 |
Why?
|
| Cloning, Molecular | 4 | 2004 | 4642 | 0.100 |
Why?
|
| Thiohydantoins | 1 | 2014 | 83 | 0.100 |
Why?
|
| Metagenome | 1 | 2019 | 798 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 752 | 0.100 |
Why?
|
| Flavones | 1 | 2013 | 24 | 0.100 |
Why?
|
| Phenotype | 6 | 2023 | 16575 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2025 | 4487 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 1077 | 0.100 |
Why?
|
| Aminoacridines | 1 | 2012 | 9 | 0.100 |
Why?
|
| Benzofurans | 1 | 2014 | 160 | 0.100 |
Why?
|
| Pyrones | 2 | 2011 | 120 | 0.100 |
Why?
|
| Suramin | 1 | 2013 | 89 | 0.100 |
Why?
|
| Cathepsins | 3 | 2009 | 358 | 0.100 |
Why?
|
| Membrane Proteins | 6 | 2019 | 8525 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 3012 | 0.100 |
Why?
|
| Cell Line | 11 | 2015 | 17392 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1684 | 0.100 |
Why?
|
| Pyridines | 4 | 2012 | 2243 | 0.100 |
Why?
|
| Benzimidazoles | 3 | 2025 | 680 | 0.100 |
Why?
|
| Cyclobutanes | 1 | 2013 | 78 | 0.100 |
Why?
|
| Naphthoquinones | 1 | 2013 | 111 | 0.100 |
Why?
|
| Sentinel Surveillance | 2 | 2020 | 283 | 0.100 |
Why?
|
| Chromatography | 1 | 2012 | 190 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 916 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2020 | 1499 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 2104 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4767 | 0.100 |
Why?
|
| Triazines | 1 | 2015 | 335 | 0.100 |
Why?
|
| Pyrazines | 1 | 2015 | 437 | 0.100 |
Why?
|
| Furans | 2 | 2011 | 306 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 1180 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase | 2 | 2009 | 121 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2020 | 1099 | 0.090 |
Why?
|
| Spleen | 1 | 2019 | 2407 | 0.090 |
Why?
|
| Imidazoles | 2 | 2009 | 1326 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1337 | 0.090 |
Why?
|
| Sequence Deletion | 1 | 2017 | 1658 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 2 | 2013 | 2003 | 0.090 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2012 | 60 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2015 | 511 | 0.090 |
Why?
|
| Biopsy | 3 | 2023 | 7311 | 0.090 |
Why?
|
| DNA Replication | 2 | 2008 | 1289 | 0.090 |
Why?
|
| Databases, Factual | 6 | 2019 | 8113 | 0.090 |
Why?
|
| Protein Conformation | 8 | 2016 | 6940 | 0.090 |
Why?
|
| Polyethylene Glycols | 2 | 2016 | 1571 | 0.090 |
Why?
|
| Vaccination | 2 | 2022 | 3302 | 0.090 |
Why?
|
| Trypanosomiasis | 1 | 2011 | 12 | 0.090 |
Why?
|
| Rural Population | 3 | 2023 | 2374 | 0.090 |
Why?
|
| Macrophages | 2 | 2025 | 6413 | 0.090 |
Why?
|
| Chagas Disease | 2 | 2012 | 295 | 0.090 |
Why?
|
| Trachoma | 1 | 2017 | 513 | 0.090 |
Why?
|
| Anthracenes | 2 | 2009 | 91 | 0.090 |
Why?
|
| Models, Biological | 7 | 2021 | 13378 | 0.090 |
Why?
|
| Darunavir | 1 | 2011 | 92 | 0.090 |
Why?
|
| Circular Dichroism | 2 | 2011 | 742 | 0.090 |
Why?
|
| Nelfinavir | 1 | 2011 | 129 | 0.090 |
Why?
|
| Middle Aged | 26 | 2021 | 222305 | 0.090 |
Why?
|
| Merozoite Surface Protein 1 | 4 | 2019 | 43 | 0.090 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2010 | 12 | 0.090 |
Why?
|
| Aspartic Acid Proteases | 1 | 2011 | 19 | 0.090 |
Why?
|
| Pharmacovigilance | 1 | 2011 | 73 | 0.090 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 544 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 4082 | 0.090 |
Why?
|
| Mass Spectrometry | 3 | 2020 | 5133 | 0.090 |
Why?
|
| Proteolysis | 2 | 2013 | 1098 | 0.080 |
Why?
|
| Cations | 1 | 2012 | 360 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2020 | 1981 | 0.080 |
Why?
|
| Spectrophotometry, Infrared | 2 | 2008 | 182 | 0.080 |
Why?
|
| Click Chemistry | 1 | 2011 | 150 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 642 | 0.080 |
Why?
|
| Cathepsin B | 2 | 2009 | 225 | 0.080 |
Why?
|
| Cytomegalovirus | 2 | 2019 | 1361 | 0.080 |
Why?
|
| Cathepsin D | 1 | 2011 | 101 | 0.080 |
Why?
|
| Indolequinones | 1 | 2010 | 20 | 0.080 |
Why?
|
| Body Height | 1 | 2014 | 836 | 0.080 |
Why?
|
| Kallikreins | 1 | 2013 | 370 | 0.080 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 24468 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1311 | 0.080 |
Why?
|
| Models, Chemical | 6 | 2011 | 1533 | 0.080 |
Why?
|
| Self Care | 1 | 2019 | 1522 | 0.080 |
Why?
|
| Motor Neuron Disease | 1 | 2012 | 188 | 0.080 |
Why?
|
| Morpholines | 1 | 1993 | 521 | 0.080 |
Why?
|
| HEK293 Cells | 6 | 2016 | 5018 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2014 | 1983 | 0.080 |
Why?
|
| Editorial Policies | 1 | 2014 | 397 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2023 | 2611 | 0.080 |
Why?
|
| Heme Oxygenase-1 | 1 | 2011 | 298 | 0.080 |
Why?
|
| Protein Transport | 2 | 2010 | 3078 | 0.080 |
Why?
|
| Hep G2 Cells | 3 | 2020 | 577 | 0.080 |
Why?
|
| Rats | 9 | 2022 | 37041 | 0.080 |
Why?
|
| Moraceae | 1 | 2009 | 1 | 0.080 |
Why?
|
| Ethnopharmacology | 1 | 2009 | 5 | 0.080 |
Why?
|
| Euphorbiaceae | 1 | 2009 | 2 | 0.080 |
Why?
|
| HIV | 2 | 2011 | 2605 | 0.080 |
Why?
|
| Double-Blind Method | 5 | 2025 | 10579 | 0.080 |
Why?
|
| Fumarates | 1 | 2009 | 66 | 0.080 |
Why?
|
| Epidemics | 1 | 2015 | 519 | 0.080 |
Why?
|
| Medicine, African Traditional | 1 | 2009 | 23 | 0.080 |
Why?
|
| Parasitology | 1 | 2009 | 63 | 0.080 |
Why?
|
| Age Factors | 9 | 2020 | 18171 | 0.080 |
Why?
|
| Plant Stems | 1 | 2009 | 36 | 0.080 |
Why?
|
| Giardia lamblia | 1 | 2011 | 186 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2025 | 5344 | 0.080 |
Why?
|
| Ethacrynic Acid | 1 | 2008 | 32 | 0.080 |
Why?
|
| Pyrimidinones | 2 | 2009 | 445 | 0.080 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 1221 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2017 | 1450 | 0.080 |
Why?
|
| Oligonucleotides | 2 | 2011 | 790 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2014 | 790 | 0.070 |
Why?
|
| Protein Sorting Signals | 1 | 2010 | 336 | 0.070 |
Why?
|
| HeLa Cells | 4 | 2017 | 3775 | 0.070 |
Why?
|
| Carbolines | 1 | 2010 | 266 | 0.070 |
Why?
|
| Aminopeptidases | 1 | 2009 | 118 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 1631 | 0.070 |
Why?
|
| HIV-1 | 5 | 2010 | 8337 | 0.070 |
Why?
|
| Urea | 1 | 2013 | 834 | 0.070 |
Why?
|
| Ubiquinone | 1 | 2012 | 343 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2015 | 2566 | 0.070 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2010 | 338 | 0.070 |
Why?
|
| Premature Birth | 1 | 2021 | 1921 | 0.070 |
Why?
|
| Metallocenes | 3 | 2016 | 15 | 0.070 |
Why?
|
| Crystallization | 3 | 2013 | 898 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2012 | 525 | 0.070 |
Why?
|
| Aza Compounds | 1 | 2009 | 170 | 0.070 |
Why?
|
| Ubiquitin | 1 | 2013 | 872 | 0.070 |
Why?
|
| Sustained Virologic Response | 2 | 2024 | 348 | 0.070 |
Why?
|
| Structural Homology, Protein | 1 | 2009 | 226 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2022 | 2544 | 0.070 |
Why?
|
| Cyclohexanes | 1 | 2009 | 158 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2020 | 4402 | 0.070 |
Why?
|
| Checklist | 2 | 2022 | 511 | 0.070 |
Why?
|
| Sporozoites | 2 | 2022 | 65 | 0.070 |
Why?
|
| Apicomplexa | 1 | 2008 | 53 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2025 | 15137 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 14317 | 0.070 |
Why?
|
| Culture Techniques | 1 | 2008 | 506 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2019 | 8563 | 0.070 |
Why?
|
| Plant Leaves | 1 | 2010 | 459 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2015 | 1107 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2014 | 3401 | 0.070 |
Why?
|
| Imidazolines | 1 | 2007 | 10 | 0.070 |
Why?
|
| Residence Characteristics | 2 | 2015 | 3058 | 0.070 |
Why?
|
| Half-Life | 3 | 2020 | 1188 | 0.070 |
Why?
|
| Blood Specimen Collection | 1 | 2009 | 251 | 0.070 |
Why?
|
| Hemin | 3 | 2014 | 46 | 0.070 |
Why?
|
| Gene Editing | 1 | 2017 | 1074 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2024 | 2672 | 0.070 |
Why?
|
| Transcriptome | 1 | 2024 | 5856 | 0.070 |
Why?
|
| Bedding and Linens | 1 | 2007 | 38 | 0.070 |
Why?
|
| Leishmaniasis | 1 | 1988 | 68 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2011 | 451 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2014 | 1045 | 0.070 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 55 | 0.070 |
Why?
|
| Viral Load | 3 | 2014 | 4979 | 0.070 |
Why?
|
| Viremia | 1 | 2013 | 1178 | 0.070 |
Why?
|
| Bone Density | 1 | 2018 | 3381 | 0.070 |
Why?
|
| Lipids | 2 | 2023 | 3342 | 0.070 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2007 | 39 | 0.070 |
Why?
|
| Urban Health Services | 1 | 2009 | 290 | 0.070 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2009 | 377 | 0.070 |
Why?
|
| Publishing | 1 | 2014 | 792 | 0.070 |
Why?
|
| Escherichia coli | 4 | 2014 | 5488 | 0.070 |
Why?
|
| Caregivers | 2 | 2020 | 3491 | 0.070 |
Why?
|
| Bacteremia | 1 | 2015 | 1132 | 0.070 |
Why?
|
| Metalloendopeptidases | 1 | 2009 | 470 | 0.070 |
Why?
|
| Schizonts | 1 | 2006 | 7 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2011 | 532 | 0.070 |
Why?
|
| Sepsis | 1 | 2019 | 2164 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2008 | 202 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3865 | 0.070 |
Why?
|
| Measles | 1 | 2008 | 150 | 0.060 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2007 | 255 | 0.060 |
Why?
|
| Anthraquinones | 1 | 2007 | 77 | 0.060 |
Why?
|
| Canada | 3 | 2019 | 2343 | 0.060 |
Why?
|
| Rectal Diseases | 1 | 1988 | 157 | 0.060 |
Why?
|
| Vitamin E | 1 | 2009 | 572 | 0.060 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 790 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2009 | 454 | 0.060 |
Why?
|
| HIV Antibodies | 2 | 2007 | 871 | 0.060 |
Why?
|
| Benzaldehydes | 1 | 2006 | 42 | 0.060 |
Why?
|
| Cell Line, Tumor | 8 | 2016 | 17592 | 0.060 |
Why?
|
| Transfection | 2 | 2006 | 6689 | 0.060 |
Why?
|
| Urban Population | 2 | 2007 | 2102 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2010 | 4470 | 0.060 |
Why?
|
| Gold | 1 | 2010 | 576 | 0.060 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 1698 | 0.060 |
Why?
|
| Erythrocyte Membrane | 2 | 2004 | 254 | 0.060 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2001 | 1183 | 0.060 |
Why?
|
| Preventive Health Services | 1 | 2011 | 665 | 0.060 |
Why?
|
| Sulfonylurea Compounds | 1 | 2007 | 132 | 0.060 |
Why?
|
| AIDS Dementia Complex | 1 | 2012 | 1039 | 0.060 |
Why?
|
| Iron | 1 | 1996 | 2614 | 0.060 |
Why?
|
| Bile Acids and Salts | 2 | 2024 | 1623 | 0.060 |
Why?
|
| Hepatitis B virus | 2 | 2022 | 714 | 0.060 |
Why?
|
| Antigens, Bacterial | 1 | 2011 | 1191 | 0.060 |
Why?
|
| Lactams | 1 | 2006 | 103 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 949 | 0.060 |
Why?
|
| Hospitalization | 3 | 2019 | 8593 | 0.060 |
Why?
|
| Plasmodium cynomolgi | 1 | 2025 | 4 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 10171 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2010 | 1420 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2007 | 347 | 0.060 |
Why?
|
| Amines | 1 | 2009 | 507 | 0.060 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 882 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 8632 | 0.060 |
Why?
|
| Housing | 3 | 2021 | 1137 | 0.060 |
Why?
|
| Oxazines | 1 | 2007 | 297 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2012 | 1353 | 0.060 |
Why?
|
| Ketones | 3 | 2014 | 326 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2010 | 5659 | 0.060 |
Why?
|
| DNA Primers | 3 | 2012 | 3456 | 0.060 |
Why?
|
| Caseins | 1 | 2005 | 158 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2007 | 370 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2011 | 2044 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2009 | 525 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2009 | 1636 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 2015 | 1112 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2009 | 1015 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 8356 | 0.050 |
Why?
|
| Sorbitol | 1 | 2004 | 91 | 0.050 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2024 | 113 | 0.050 |
Why?
|
| Neutropenia | 1 | 2008 | 580 | 0.050 |
Why?
|
| Plant Roots | 1 | 2007 | 358 | 0.050 |
Why?
|
| Thiazepines | 1 | 2024 | 22 | 0.050 |
Why?
|
| Decidua | 1 | 2025 | 158 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 1426 | 0.050 |
Why?
|
| Pharmacognosy | 1 | 2003 | 8 | 0.050 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2003 | 43 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2024 | 1726 | 0.050 |
Why?
|
| Acetonitriles | 1 | 2024 | 49 | 0.050 |
Why?
|
| Buspirone | 1 | 2003 | 39 | 0.050 |
Why?
|
| Herpesviridae Infections | 1 | 2009 | 727 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2008 | 572 | 0.050 |
Why?
|
| AIDS Serodiagnosis | 1 | 2006 | 409 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 1240 | 0.050 |
Why?
|
| Benzopyrans | 1 | 2024 | 114 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 3 | 2009 | 375 | 0.050 |
Why?
|
| Gravidity | 1 | 2023 | 47 | 0.050 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2016 | 1690 | 0.050 |
Why?
|
| Point Mutation | 2 | 2017 | 1705 | 0.050 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 31501 | 0.050 |
Why?
|
| Drug Stability | 2 | 2018 | 401 | 0.050 |
Why?
|
| Chromatography, Gas | 1 | 2003 | 286 | 0.050 |
Why?
|
| Peptide Fragments | 3 | 2014 | 4949 | 0.050 |
Why?
|
| Catalysis | 2 | 2010 | 1585 | 0.050 |
Why?
|
| Membranes | 1 | 2003 | 180 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 1730 | 0.050 |
Why?
|
| Frameshift Mutation | 1 | 2024 | 343 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2008 | 662 | 0.050 |
Why?
|
| Monkeypox virus | 1 | 2023 | 53 | 0.050 |
Why?
|
| Pregnancy Outcome | 2 | 2025 | 2272 | 0.050 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2023 | 160 | 0.050 |
Why?
|
| Cell Membrane | 2 | 2007 | 5208 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 3 | 2011 | 6251 | 0.050 |
Why?
|
| Methylamines | 1 | 2024 | 206 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 232 | 0.050 |
Why?
|
| Piperonyl Butoxide | 1 | 2022 | 29 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 1759 | 0.050 |
Why?
|
| Cinchona Alkaloids | 1 | 2002 | 2 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 11665 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2009 | 2252 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2010 | 1275 | 0.050 |
Why?
|
| Sugars | 1 | 2023 | 108 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 627 | 0.050 |
Why?
|
| Hydrazones | 1 | 2022 | 97 | 0.050 |
Why?
|
| Age Distribution | 2 | 2009 | 2888 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2006 | 903 | 0.050 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2024 | 251 | 0.050 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2024 | 355 | 0.050 |
Why?
|
| Pantothenic Acid | 1 | 2022 | 33 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 493 | 0.050 |
Why?
|
| Metformin | 1 | 2009 | 830 | 0.050 |
Why?
|
| Dithiothreitol | 1 | 2002 | 133 | 0.050 |
Why?
|
| Endoglin | 1 | 2022 | 106 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 22002 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 3 | 2017 | 1519 | 0.050 |
Why?
|
| Aldehydes | 1 | 2003 | 314 | 0.050 |
Why?
|
| Culture Media | 1 | 2005 | 1133 | 0.050 |
Why?
|
| Lysosomes | 1 | 1989 | 1353 | 0.050 |
Why?
|
| Hemolysis | 1 | 2004 | 444 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2013 | 1764 | 0.050 |
Why?
|
| Terpenes | 1 | 2003 | 251 | 0.050 |
Why?
|
| Protein Renaturation | 1 | 2001 | 9 | 0.050 |
Why?
|
| Insecticide Resistance | 1 | 2022 | 107 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2003 | 370 | 0.040 |
Why?
|
| Pyridones | 1 | 2008 | 842 | 0.040 |
Why?
|
| Home Care Services | 1 | 2009 | 829 | 0.040 |
Why?
|
| Health Status | 1 | 2014 | 4463 | 0.040 |
Why?
|
| Angola | 2 | 2011 | 9 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2006 | 1323 | 0.040 |
Why?
|
| Congo | 1 | 2021 | 12 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 1697 | 0.040 |
Why?
|
| Disulfides | 1 | 2003 | 531 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2004 | 752 | 0.040 |
Why?
|
| Multigene Family | 1 | 2007 | 1655 | 0.040 |
Why?
|
| Disease Management | 1 | 2012 | 2388 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2010 | 6743 | 0.040 |
Why?
|
| Cambodia | 1 | 2021 | 170 | 0.040 |
Why?
|
| Rodent Diseases | 1 | 2002 | 201 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2005 | 1555 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2023 | 334 | 0.040 |
Why?
|
| Endocytosis | 2 | 2021 | 1364 | 0.040 |
Why?
|
| Cricetulus | 2 | 2015 | 1208 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2007 | 704 | 0.040 |
Why?
|
| Body Temperature | 2 | 2006 | 963 | 0.040 |
Why?
|
| Pan American Health Organization | 1 | 2020 | 6 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 4601 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2023 | 5249 | 0.040 |
Why?
|
| Thapsigargin | 2 | 2010 | 167 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 311 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 337 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2008 | 5820 | 0.040 |
Why?
|
| Water | 1 | 2012 | 3429 | 0.040 |
Why?
|
| CHO Cells | 2 | 2015 | 1795 | 0.040 |
Why?
|
| Esterases | 1 | 2020 | 117 | 0.040 |
Why?
|
| Cycloaddition Reaction | 1 | 2020 | 65 | 0.040 |
Why?
|
| Binomial Distribution | 1 | 2020 | 31 | 0.040 |
Why?
|
| Organothiophosphorus Compounds | 1 | 2020 | 56 | 0.040 |
Why?
|
| Antibody Formation | 2 | 2015 | 1113 | 0.040 |
Why?
|
| Evolution, Molecular | 2 | 2007 | 3374 | 0.040 |
Why?
|
| CpG Islands | 1 | 2025 | 1401 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 158 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2003 | 2084 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2009 | 10000 | 0.040 |
Why?
|
| Inclusion Bodies | 1 | 2001 | 367 | 0.040 |
Why?
|
| Rodentia | 1 | 2002 | 411 | 0.040 |
Why?
|
| Zoonoses | 1 | 2023 | 489 | 0.040 |
Why?
|
| Cytosol | 1 | 2003 | 1178 | 0.040 |
Why?
|
| Mitochondrial Diseases | 1 | 2024 | 371 | 0.040 |
Why?
|
| North America | 1 | 2023 | 1539 | 0.040 |
Why?
|
| Glycerol | 1 | 2001 | 369 | 0.040 |
Why?
|
| Protein Domains | 1 | 2024 | 1265 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2013 | 390 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2019 | 3347 | 0.040 |
Why?
|
| Directly Observed Therapy | 1 | 2020 | 136 | 0.040 |
Why?
|
| ROC Curve | 2 | 2019 | 4173 | 0.040 |
Why?
|
| Oligopeptides | 2 | 2018 | 1666 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2019 | 110 | 0.040 |
Why?
|
| Tyrosine | 1 | 2003 | 1435 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 4981 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 2007 | 1245 | 0.040 |
Why?
|
| Aged | 11 | 2021 | 170742 | 0.040 |
Why?
|
| Esters | 1 | 2020 | 382 | 0.040 |
Why?
|
| Cricetinae | 2 | 2015 | 3475 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2007 | 1572 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2003 | 2044 | 0.040 |
Why?
|
| Seeds | 2 | 2013 | 271 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 2230 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2022 | 993 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2012 | 3783 | 0.040 |
Why?
|
| Aging | 1 | 2021 | 13610 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2024 | 1254 | 0.040 |
Why?
|
| Cryptosporidium | 1 | 2019 | 130 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2022 | 497 | 0.040 |
Why?
|
| Rhinovirus | 1 | 2019 | 163 | 0.040 |
Why?
|
| Body Weight | 2 | 2023 | 4580 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 575 | 0.040 |
Why?
|
| Myanmar | 1 | 2018 | 142 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 2003 | 2329 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2022 | 474 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 2 | 2008 | 256 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 1986 | 0.030 |
Why?
|
| Virus Replication | 1 | 2008 | 3310 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 432 | 0.030 |
Why?
|
| Plasmids | 1 | 2004 | 2718 | 0.030 |
Why?
|
| Malawi | 1 | 2019 | 452 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2014 | 2411 | 0.030 |
Why?
|
| Plasminogen | 1 | 1998 | 188 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2025 | 1632 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 798 | 0.030 |
Why?
|
| Antibodies | 1 | 2006 | 2683 | 0.030 |
Why?
|
| Glutathione | 1 | 2002 | 1186 | 0.030 |
Why?
|
| Thermodynamics | 2 | 2014 | 1762 | 0.030 |
Why?
|
| Merozoites | 1 | 2017 | 14 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2024 | 4792 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 3349 | 0.030 |
Why?
|
| Biological Evolution | 1 | 2008 | 2441 | 0.030 |
Why?
|
| Fibroblasts | 2 | 2016 | 5458 | 0.030 |
Why?
|
| Polymers | 1 | 2005 | 1533 | 0.030 |
Why?
|
| Disease Reservoirs | 1 | 2019 | 368 | 0.030 |
Why?
|
| Logistic Models | 3 | 2017 | 12750 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 5339 | 0.030 |
Why?
|
| Species Specificity | 2 | 2012 | 4440 | 0.030 |
Why?
|
| Antioxidants | 1 | 2005 | 1989 | 0.030 |
Why?
|
| Chemical Phenomena | 2 | 2009 | 602 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 61428 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 2860 | 0.030 |
Why?
|
| Cysteine | 1 | 2002 | 1178 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 2009 | 561 | 0.030 |
Why?
|
| Neglected Diseases | 1 | 2017 | 111 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 863 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 4677 | 0.030 |
Why?
|
| Cytokines | 2 | 2025 | 8221 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 5280 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2025 | 1970 | 0.030 |
Why?
|
| Bortezomib | 1 | 2018 | 426 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 5690 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 13245 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 409 | 0.030 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2016 | 166 | 0.030 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 26988 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2010 | 638 | 0.030 |
Why?
|
| Arginine | 1 | 2001 | 1209 | 0.030 |
Why?
|
| Gallbladder | 1 | 2017 | 241 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 1305 | 0.030 |
Why?
|
| Anemia | 2 | 2015 | 1393 | 0.030 |
Why?
|
| Cryptolepis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Mali | 1 | 2015 | 111 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2015 | 103 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2006 | 23471 | 0.030 |
Why?
|
| Fetus | 1 | 2024 | 2804 | 0.030 |
Why?
|
| Baculoviridae | 1 | 1995 | 193 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2023 | 1569 | 0.030 |
Why?
|
| Puromycin | 1 | 2014 | 66 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 3672 | 0.030 |
Why?
|
| Coumarins | 1 | 1995 | 135 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 776 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2015 | 125 | 0.030 |
Why?
|
| Monocytes | 1 | 2024 | 2420 | 0.030 |
Why?
|
| Internet | 1 | 2007 | 3562 | 0.030 |
Why?
|
| Chymotrypsin | 1 | 1995 | 178 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 140 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2020 | 1116 | 0.030 |
Why?
|
| Fluorescent Dyes | 2 | 2013 | 2753 | 0.030 |
Why?
|
| Enterostomy | 1 | 2014 | 33 | 0.030 |
Why?
|
| Health Facilities | 1 | 2018 | 533 | 0.030 |
Why?
|
| Insect Bites and Stings | 1 | 2015 | 104 | 0.030 |
Why?
|
| Oxamic Acid | 1 | 2013 | 8 | 0.030 |
Why?
|
| Analytic Sample Preparation Methods | 1 | 2014 | 24 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 5539 | 0.030 |
Why?
|
| Freezing | 1 | 2015 | 306 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 1475 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2015 | 360 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2009 | 2520 | 0.030 |
Why?
|
| Dogs | 2 | 2017 | 9991 | 0.030 |
Why?
|
| Porphyrins | 1 | 2015 | 217 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 1424 | 0.030 |
Why?
|
| Computer Simulation | 3 | 2013 | 8146 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 59 | 0.020 |
Why?
|
| Fatigue | 1 | 2022 | 2016 | 0.020 |
Why?
|
| Ascites | 1 | 2015 | 385 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2019 | 730 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2014 | 534 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2015 | 1068 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 10832 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 3545 | 0.020 |
Why?
|
| Syndrome | 1 | 2019 | 3009 | 0.020 |
Why?
|
| Prognosis | 3 | 2023 | 25695 | 0.020 |
Why?
|
| China | 1 | 2018 | 2399 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2015 | 466 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 2501 | 0.020 |
Why?
|
| Salmonella | 1 | 2015 | 452 | 0.020 |
Why?
|
| Models, Statistical | 2 | 2015 | 4271 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 2015 | 703 | 0.020 |
Why?
|
| Cyclization | 1 | 2013 | 250 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 11328 | 0.020 |
Why?
|
| Cell Proliferation | 3 | 2015 | 11496 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2014 | 844 | 0.020 |
Why?
|
| Benzoxazoles | 1 | 2012 | 81 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 7116 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 368 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 6600 | 0.020 |
Why?
|
| Gestational Age | 1 | 2021 | 4238 | 0.020 |
Why?
|
| Organophosphates | 1 | 2022 | 1159 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2022 | 2393 | 0.020 |
Why?
|
| Heterozygote | 2 | 2009 | 2769 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 10376 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 820 | 0.020 |
Why?
|
| Oocysts | 1 | 2011 | 115 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2559 | 0.020 |
Why?
|
| Nigericin | 1 | 2010 | 19 | 0.020 |
Why?
|
| History, 17th Century | 1 | 2011 | 100 | 0.020 |
Why?
|
| Self Report | 1 | 2023 | 4264 | 0.020 |
Why?
|
| Monensin | 1 | 2010 | 53 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2024 | 3416 | 0.020 |
Why?
|
| History, 18th Century | 1 | 2011 | 156 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2013 | 413 | 0.020 |
Why?
|
| Tanzania | 1 | 2012 | 554 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 1007 | 0.020 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 105 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 26761 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 4061 | 0.020 |
Why?
|
| Datasets as Topic | 1 | 2014 | 773 | 0.020 |
Why?
|
| Linear Models | 1 | 2020 | 5463 | 0.020 |
Why?
|
| Leadership | 1 | 2020 | 1428 | 0.020 |
Why?
|
| Feces | 1 | 2019 | 2307 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 8486 | 0.020 |
Why?
|
| Alkylation | 1 | 2010 | 158 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2011 | 668 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2012 | 338 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2012 | 1196 | 0.020 |
Why?
|
| Diamide | 1 | 2009 | 14 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 346 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2022 | 4456 | 0.020 |
Why?
|
| Guanidines | 1 | 2011 | 282 | 0.020 |
Why?
|
| Program Evaluation | 2 | 2009 | 3280 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2010 | 258 | 0.020 |
Why?
|
| Electrophoresis, Capillary | 1 | 2010 | 105 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2000 | 2848 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 487 | 0.020 |
Why?
|
| History, 19th Century | 1 | 2011 | 458 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 925 | 0.020 |
Why?
|
| Reference Values | 2 | 2008 | 5518 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2024 | 6345 | 0.020 |
Why?
|
| Algorithms | 3 | 2021 | 15044 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2010 | 291 | 0.020 |
Why?
|
| Biotransformation | 1 | 2009 | 353 | 0.020 |
Why?
|
| RNA | 1 | 2022 | 3767 | 0.020 |
Why?
|
| Ileum | 1 | 2012 | 703 | 0.020 |
Why?
|
| Registries | 1 | 2025 | 8805 | 0.020 |
Why?
|
| Host-Parasite Interactions | 1 | 2011 | 393 | 0.020 |
Why?
|
| Nucleosides | 1 | 2010 | 265 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 1049 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 1653 | 0.020 |
Why?
|
| Genes | 1 | 1992 | 1422 | 0.020 |
Why?
|